VYNE Therapeutics Stock
VYNE Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David T. Domzalski
- Employees
- 10
- Market cap
- $19 M
- IPO
- 25/01/2018
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe…
VYNE Therapeutics stock: price history
1D
+12.2%
1W
-29.3%
1M
-11.9%
6M
-1.1%
YTD
-1.6%
1Y
-60.9%
2Y
-72.7%
5Y
-98.8%
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~6% weaker price swings than usual
VYNE Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 09/09/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
VYNE Therapeutics is a pharmaceutical company specializing in the discovery and development of therapies for immune-mediated inflammatory diseases. The company maintains a pipeline of various drug candidates, including FCD105 for the treatment of acne vulgaris and BET inhibitors for different skin conditions at various stages of clinical development. Business operations focus on researching and advancing these proprietary drugs clinically to progressively qualify them for the pharmaceutical market.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about VYNE Therapeutics
Analyst assessment of VYNE Therapeutics
PRICE TARGET LOW
US$5.75
CONSENSUS
US$5.75
MEDIAN
US$5.75
PRICE TARGET HIGH
US$5.75
0
STRONG BUY
1
BUY
1
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 30/07/2025
VYNE Therapeutics stock metrics
P/E
-0.04
P/B
43.99
EV/EBITDA
-0.42
RETURN ON EQUITY
-95,382.7%
NET MARGIN
-4,646.1%
DEBT/EQUITY
0
DIVIDEND YIELD
70.5%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.9%
FLOAT SHARES
613,692
AVG. DAILY VOLUME (30D)
30,515
Insider transactions (SEC)
RTW Fund Group GP, LLC
Domzalski David
Harsch Mutya
Zeronda Tyler
Stuart Iain
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about VYNE Therapeutics stock
What does VYNE Therapeutics do?
VYNE Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David T. Domzalski, the company employs around 10 people.
The IPO was on 25/01/2018; the stock trades on NASDAQ under the ticker VYNE.
What do analysts say about VYNE Therapeutics stock?
2 analysts rate the stock, the consensus is Buy (as of 30/07/2025).
The average price target is US$5.75, ranging from US$5.75 to US$5.75, with a median of US$5.75.
This is an external assessment, not a statement by Market Jury.
When does VYNE Therapeutics report next?
Around past earnings, price swings were roughly -6% stronger than usual.
Does VYNE Therapeutics pay a dividend?
Yes. The last dividend was US$0.40 per share.
The dividend yield is 70.5% (as of 30/06/2026).
Which stocks are comparable to VYNE Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get VYNE Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess VYNE Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.